Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
59 hedge funds and large institutions have $51M invested in Avadel Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 7 increasing their positions, 19 reducing their positions, and 17 closing their positions.
0.9% less ownership
Funds ownership: 50.31% → 49.41% (-0.9%)
9% less funds holding
Funds holding: 65 → 59 (-6)
35% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 17
42% less capital invested
Capital invested by funds: $88.5M → $51M (-$37.5M)
63% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 19
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $76K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$2.66M |
| 2 |
FI
Fosun International
Hong Kong,
China
|
+$1.15M |
| 3 |
BC
Broadfin Capital
New York
|
+$1.05M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$616K |
| 5 |
HCM
Highbridge Capital Management
New York
|
+$333K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.56M |
| 2 |
BlackRock
New York
|
-$2.12M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$1.98M |
| 4 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$661K |
| 5 |
AA
ALPS Advisors
Denver,
Colorado
|
-$311K |
AVDL Hedge Fund Activity: Q4 2018 in Review
59 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q4 2018, worth a combined $51M — down 42% from $88.5M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of AVDL and 11 opened new positions — a net loss of 6 holders — while 19 trimmed existing stakes and 7 added.
The largest buyer was Brandes Investment Partners, adding an estimated $2.66M. The largest seller was Deutsche Bank, cutting an estimated $2.56M.
- 59 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q4 2018, down from 65 in Q3 2018.
- Funds reported $51M of Avadel Pharmaceuticals stock for Q4 2018, down 42% quarter-over-quarter.
- 11 funds opened new Avadel Pharmaceuticals positions in Q4 2018 and 17 closed out, a net change of -6 holders.
- The largest Avadel Pharmaceuticals buyer in Q4 2018 was Brandes Investment Partners, an estimated $2.66M added.
- The largest Avadel Pharmaceuticals seller in Q4 2018 was Deutsche Bank, an estimated $2.56M sold.
Based on aggregated 13F filings for Q4 2018.